- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03430947
Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases (RadioCoBRIM)
An Open-label Phase II Multicenter Study of Vemurafenib (Zelboraf®) Plus Cobimetinib (Cotellic®) After Radiosurgery in Patients With Active BRAF-V600-mutant Melanoma Brain Metastases
This is a phase II, open label, non-randomised study of vemurafenib and cobimetinib after radiosurgery in adult patients with BRAFV600-mutant melanoma brain metastases. All patients will receive vemurafenib 960 mg twice a day on days 1 - 28 combined with cobimetinib 60 mg once a day on days 1 - 21 of each 28-day treatment cycle until disease progression, drug toxicity or death.
The primary objective of this study is to determine the best overall response rate (BORR) in the brain. The extracranial BORR, intra- and extracranial duration of response, progression-free survival and overall survival, adverse events, quality of life and radiomics features predicting long-term local control of brain metastases and treatment-related toxicity will also be examined.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Dresden, Germany, 01307
- Technische Universitat Dresden
-
Heidelberg, Germany, 69120
- Ruprecht-Karls-University of Heidelberg, Faculty of Medicine
-
Tuebingen, Germany, 72076
- Eberhard Karls University of Tübingen, University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria
- Signed informed consent
- Female and male patients ≥ 18 years of age
- Histologically confirmed metastatic melanoma (stage IV, per AJCC staging), carrying BRAF V600-mutation
Performed SRS 14 ±7 days before baseline using a harmonized protocol in patients with at least one measurable intracranial target lesion for which the following criteria are met:
- Previously untreated (Lesions in previously irradiated area should not be selected)
- Largest diameter of ≥ 0.5 but ≤ 4 cm as determined by contrast-enhanced MRI and
- ≤ 10 brain metastases
- ECOG performance status 0 - 2
- Life expectancy ≥ 12 weeks
Adequate bone marrow function as indicated by the following:
- ANC ≥ 1500/µL,
- Platelets ≥ 100,000/µL and
- Hemoglobin ≥ 9 g/dL
- Adequate renal function, as indicated by creatinine ≤ 1.5 x ULN
- Adequate liver function, as indicated by bilirubin < 1.5 x ULN and AST and ALT < 3 x ULN (documented liver metastases: AST and ALT < 5 x ULN)
Adequate coagulation within 28 days prior to baseline visit
- Patients without therapeutic anticoagulation: INR or aPTT ≤ 1.5 x ULN
- Patients receiving therapeutic anticoagulation: stable anticoagulation regimen and stable INR
- Able to swallow pills
Exclusion criteria
- Symptomatic brain metastases requiring immediate local interventions such as neurosurgery or radiosurgery
- Leptomeningeal disease (also synchronous with brain metastases)
- Prior therapy with BRAF or MEK inhibitors within 12 weeks prior to baseline visit (prior therapies for metastatic melanoma including chemo-, cytokine-, immuno-, biological and vaccine-therapy will be al-lowed) A period of at least 6 weeks must be observed between the last dose of ipilimumab and the first administration of the study treatments. Prior treatment with anti-programmed cell death (PD)-1 or anti-PD ligand 1 (PD-L1) is allowed.
- Prior whole brain irradiation (Patients with prior local therapy of brain metas-tases are eligible)
- Patients receiving therapeutic steroids are not stable on corticoster-oids 2 weeks before SRS
- Active and uncontrolled infection
Known HIV infection or active HBV or HCV infection
- Active HBV infection (chronic and acute), defined as having a posi-tive hepatitis B surface antigen (HBsAg) test at screening (past or resolved HBV infection, defined as negative HBsAg test and a posi-tive total hepatitis B core antibody test at screening, are eligible)
- Active HCV infection, defined as positive HCV antibody test and positive HCV RNA test at screening
- Intracranial radiation therapy within 14 days prior to SRS
- Extracranial radiation therapy within the last 14 days prior to baseline visit
- Treatment with strong CYP3A4/5 inhibitors (e.g. ketoconazole) and inducers (e.g. phenytoin, carbamazepine). (anticonvulsant levetiracetam is allowed; patient should be stable on levetiracetam for 2 weeks)
- Unresolved toxicity of National Cancer Institute Common Terminology Crite-ria for Adverse Events, version 4.0 (NCI v4.0) [NCI, 2009] Grade 2 or higher from previous anti-cancer therapy, except alopecia.
- Conditions that will interfere significantly with the absorption of drugs (e.g. Colitis ulcerosa)
Inability to undergo MRI secondary to:
- Metal,
- Claustrophobia, or
- Gadolinium contrast allergy
- Previous malignancies active within the last 3 years, with the exception of locally curable cancers that have been treated to complete remis-sion or untreated stage I chronic lymphoid leukemia.
- Unwillingness or inability to comply with study and follow-up procedures
- Known hypersensitivity to any of the excipients of cobimetinib and vemuraf-enib
The following foods/supplements are prohibited at least 7 days prior to initia-tion of and during study treatment:
- St. John's wort or hyperforin (potent cytochrome P450 CYP3A4 enzyme inducer)
- Grapefruit juice (potent cytochrome P450 CYP3A4 enzyme inhibitor)
- Patient is included in another interventional trial
- Use of any investigational or non-registered product within 4 weeks prior to baseline visit
Woman of childbearing age with the exception they meet at least one of the following criteria:
- Post-menopausal,
- Sterilization,
- Consistently & correct application of contraceptives (Pearl Index < 1%),
- sexual abstinence, or
- vasectomy of the partner
- Pregnant or lactating women
History, risk factor or retinal pathology that increases the risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR): evidence of retinal pathology that is considered a risk factor for RVO or CSR, or a history of retinal detachment, central serous chorioretinopathy or reti-nal vein thrombosis. The risk factors for RVO are listed below:
- Uncontrolled glaucoma with intraocular pressures > 21 mm Hg,
- Serum cholesterol ≥ Grade 2 (≥ 7.75 mmol/L),
- Hypertriglyceridemia ≥ Grade 2 (≥ 3.42 mmol/L), Hyperglycemia (fasting) ≥ Grade 2 (≥ 8.9 mmol/L).
History of clinically significant cardiac dysfunction including:
- Myocardial infarction,
- Severe/unstable angina pectoris,
- Symptomatic congestive heart failure (NYHA stage ≥ 2),
- cerebrovascular accident or transient ischemic attack within the previous 6 months,
- History of congenital long QT syndrome or mean QTcF > 450 msec or uncorrectable electrolyte abnormalities,
- Hypertension > Grade 2 not controlled by medications
- Left ventricular ejection fraction (LVEF) < 50%, or
- Uncontrolled arrhythmias
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
all patients will be treated with Vemurafenib + Cobimetinib
|
Vemurafenib (960 mg twice a day) will be taken on days 1 - 28 of each 28-day treatment cycle.
Cobimetinib (60 mg once a day) will be taken on days 1 - 21 of each 28-day treatment cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best overall response rate in the brain
Time Frame: 2 years
|
rate of patients with complete response or partial response (intracranial)
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Extracranial best overall response rate
Time Frame: 2 years
|
rate of patients with complete response or partial response (extracranial)
|
2 years
|
Best overall response rate calculated for the whole body tumor sites
Time Frame: 2 years
|
rate of patients with complete response or partial response
|
2 years
|
Intracranial duration of response
Time Frame: 2 years
|
time from best overall response in the brain to first documentation of intracranial progression
|
2 years
|
Extracranial duration of response
Time Frame: 2 years
|
time from best extracranial overall response to first documentation of extracranial progression
|
2 years
|
Progression-free survival
Time Frame: 2 years
|
time from first dose of study treatment until progression
|
2 years
|
Overall survival
Time Frame: 2 years
|
time from first dose of study treatment until death due to any cause
|
2 years
|
Incidence of adverse events
Time Frame: 2 years
|
Adverse events by type, frequency and severity using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03; number of patients who withdraw from the study due to intolerable adverse events.
|
2 years
|
Radiomics for long-term control of brain metastases
Time Frame: every 6 weeks up to 2 years
|
Radiomics features predictive of long-term local control of brain metastases using Magnetic Resonance Imaging
|
every 6 weeks up to 2 years
|
Radiomics for intracranial Treatment-related toxicity
Time Frame: every 6 weeks up to 2 years
|
Radiomics features predicting treatment-related toxicity (e.g.
radionecrosis, hemorrhage, edema) using Magnetic Resonance Imaging
|
every 6 weeks up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Friedegund Meier, MD, Technische Universitat Dresden
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neoplastic Processes
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Neuroendocrine Tumors
- Nevi and Melanomas
- Neoplasm Metastasis
- Brain Neoplasms
- Melanoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Vemurafenib
Other Study ID Numbers
- TUD-CoBRIM-67
- 2017-000768-13 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Metastases
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingRecurrent Brain Metastases | Progressive Brain MetastasesUnited States
-
AC Camargo Cancer CenterCarl Zeiss Meditec AGTerminatedBrain Metastases, Adult | Central Nervous System MetastasesBrazil
-
Rigshospitalet, DenmarkRecruitingCancer | Brain Metastases, AdultDenmark
-
Susanne RogersUniversity of Basel; Technical University of MunichRecruitingBrain Metastases, AdultSwitzerland
-
British Columbia Cancer AgencyVarian Medical SystemsRecruitingBrain Metastases, AdultCanada
-
IRCCS San RaffaeleRecruitingBrain Metastases, AdultItaly
-
AHS Cancer Control AlbertaRecruitingBrain Metastases, AdultCanada
-
University Health Network, TorontoRecruiting
-
Centre Francois BaclesseGroupement Interrégional de Recherche Clinique et d'Innovation; ANOCEF/IGCNORecruitingHemorrhagic Brain MetastasesFrance
-
Duke UniversityVarian Medical SystemsCompleted
Clinical Trials on Vemurafenib
-
Inova Health Care ServicesGenentech, Inc.Withdrawn
-
Center Eugene MarquisCompletedMalignant MelanomaFrance
-
Hoffmann-La RocheCompletedMalignant MelanomaUnited States, Australia
-
Hoffmann-La RocheTerminatedMalignant MelanomaUnited States, France, Australia, United Kingdom, Italy, Spain, Germany, Israel, Poland, Slovakia
-
Mohammed M MilhemGenentech, Inc.TerminatedMelanoma | Metastatic Melanoma | BRAF-mutated Metastatic Melanoma | V600EBRAF-mutated Metastatic MelanomaUnited States
-
Shanghai Kechow Pharma, Inc.Not yet recruiting
-
Daiichi Sankyo, Inc.PlexxikonTerminatedV600-mutated BRAF Unresectable Melanoma | V600-mutated BRAF Metastatic Melanoma | Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF InhibitorUnited States, Germany, France
-
Celldex TherapeuticsMemorial Sloan Kettering Cancer CenterCompletedThyroid CancerUnited States
-
Radboud University Medical CenterThe Netherlands Cancer Institute; IsalaRecruitingMelanoma, Malignant, of Soft PartsNetherlands
-
Grupo Español Multidisciplinar de MelanomaRoche Farma, S.A; Pivotal S.L.Completed